Clinical Implications of Antiviral Resistance in Influenza

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2015 Sep 22

PMID 26389935

Citations 79

Authors

Timothy C M Li

Martin C W Chan

Nelson Lee

Affiliations

Soon will be listed here.

Abstract

Influenza is a major cause of severe respiratory infections leading to excessive hospitalizations and deaths globally; annual epidemics, pandemics, and sporadic/endemic avian virus infections occur as a result of rapid, continuous evolution of influenza viruses. Emergence of antiviral resistance is of great clinical and public health concern. Currently available antiviral treatments include four neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, laninamivir), M2-inibitors (amantadine, rimantadine), and a polymerase inhibitor (favipiravir). In this review, we focus on resistance issues related to the use of neuraminidase inhibitors (NAIs). Data on primary resistance, as well as secondary resistance related to NAI exposure will be presented. Their clinical implications, detection, and novel therapeutic options undergoing clinical trials are discussed.

Citing Articles

Monitoring Influenza A Virus Entry Using Quantitative Fluorescence Microscopy.

Pathak T, Gupta K, Kumar N, Banerjee I Methods Mol Biol. 2025; 2890:103-123.

PMID: 39890723 DOI: 10.1007/978-1-0716-4326-6_5.

Advances and Challenges in Antiviral Development for Respiratory Viruses.

De Jesus-Gonzalez L, Leon-Juarez M, Lira-Hernandez F, Rivas-Santiago B, Velazquez-Cervantes M, Mendez-Delgado I Pathogens. 2025; 14(1).

PMID: 39860981 PMC: 11768830. DOI: 10.3390/pathogens14010020.

Inhibition of cap-dependent endonuclease in influenza virus with ADC189: a pre-clinical analysis and phase I trial.

Wei J, Deng Y, Zhu X, Xiao X, Yang Y, Tang C Front Med. 2025; .

PMID: 39832023 DOI: 10.1007/s11684-024-1115-1.

Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Wang Y, Wang H, Zhang Y, Ma A, Liu D, Li X Nat Med. 2025; 31(2):639-646.

PMID: 39775042 DOI: 10.1038/s41591-024-03419-3.

Drug resistance and possible therapeutic options against influenza A virus infection over past years.

Asif Raza M, Ashraf M Arch Microbiol. 2024; 206(12):458.

PMID: 39499323 DOI: 10.1007/s00203-024-04181-3.

References

Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin M, Boivin G . Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med. 2009; 361(23):2296-7. DOI: 10.1056/NEJMc0910060. View

Moghadas S, Bowman C, Rost G, Fisman D, Wu J . Post-exposure prophylaxis during pandemic outbreaks. BMC Med. 2009; 7:73. PMC: 2794871. DOI: 10.1186/1741-7015-7-73. View

Smee D, Hurst B, Wong M, Bailey K, Bart Tarbet E, Morrey J . Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother. 2009; 54(1):126-33. PMC: 2798555. DOI: 10.1128/AAC.00933-09. View

Gaur A, Bagga B, Barman S, Hayden R, Lamptey A, Hoffman J . Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med. 2009; 362(1):88-9. DOI: 10.1056/NEJMc0910893. View

Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Mai Le Q . T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A. 2010; 107(2):882-7. PMC: 2818889. DOI: 10.1073/pnas.0909603107. View

Baz M, Abed Y, Simon P, Hamelin M, Boivin G . Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis. 2010; 201(5):740-5. DOI: 10.1086/650464. View

Okomo-Adhiambo M, Demmler-Harrison G, Deyde V, Sheu T, Xu X, Klimov A . Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother. 2010; 54(5):1834-41. PMC: 2863645. DOI: 10.1128/AAC.01608-09. View

Sleeman K, Mishin V, Deyde V, Furuta Y, Klimov A, Gubareva L . In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother. 2010; 54(6):2517-24. PMC: 2876376. DOI: 10.1128/AAC.01739-09. View

Lee N, Choi K, Chan P, Hui D, Lui G, Wong B . Outcomes of adults hospitalised with severe influenza. Thorax. 2010; 65(6):510-5. DOI: 10.1136/thx.2009.130799. View

10.

Ngai K, Lam W, Lee N, Leung T, Hui D, Chan P . Allele-specific conventional reverse-transcription polymerase chain reaction as a screening assay for discriminating influenza a H1N1 (H275Y) oseltamivir-resistant and wild-type viruses. J Med Virol. 2010; 82(8):1295-8. DOI: 10.1002/jmv.21783. View

11.

Tramontana A, George B, Hurt A, Doyle J, Langan K, Reid A . Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis. 2010; 16(7):1068-75. PMC: 3321901. DOI: 10.3201/eid1607.091691. View

12.

Nguyen H, Sheu T, Mishin V, Klimov A, Gubareva L . Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother. 2010; 54(9):3671-7. PMC: 2934949. DOI: 10.1128/AAC.00581-10. View

13.

Adisasmito W, Chan P, Lee N, Oner A, Gasimov V, Aghayev F . Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis. 2010; 202(8):1154-60. DOI: 10.1086/656316. View

14.

Inoue M, Barkham T, Leo Y, Chan K, Chow A, Wong C . Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours. Emerg Infect Dis. 2010; 16(10):1633-6. PMC: 3294403. DOI: 10.3201/eid1610.100688. View

15.

van der Vries E, Stelma F, Boucher C . Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med. 2010; 363(14):1381-2. DOI: 10.1056/NEJMc1003749. View

16.

Watanabe A, Chang S, Kim M, Chu D, Ohashi Y . Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010; 51(10):1167-75. DOI: 10.1086/656802. View

17.

Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A . Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010; 7(11):e1000362. PMC: 2970549. DOI: 10.1371/journal.pmed.1000362. View

18.

Renaud C, Pergam S, Polyak C, Jain R, Kuypers J, Englund J . Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis. 2010; 12(6):513-7. PMC: 3024056. DOI: 10.1111/j.1399-3062.2010.00582.x. View

19.

Moore C, Galiano M, Lackenby A, Abdelrahman T, Barnes R, Evans M . Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis. 2010; 203(1):18-24. PMC: 3086444. DOI: 10.1093/infdis/jiq007. View

20.

Tamura D, Sugaya N, Ozawa M, Takano R, Ichikawa M, Yamazaki M . Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis. 2011; 52(4):432-7. PMC: 3062105. DOI: 10.1093/cid/ciq183. View